ALX Oncology's clinical trial results for evorpacept will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium.
Quiver AI Summary
ALX Oncology Holdings Inc. announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, scheduled for January 23-25, 2025, in San Francisco. The ASPEN-06 trial evaluates evorpacept, a CD47-blocking therapy, in combination with trastuzumab, CYRAMZA, and paclitaxel for treating HER2-positive gastric/gastroesophageal junction cancer in patients who previously received anti-HER2 treatment. The presentation, led by Dr. Kohei Shitara, will provide the final analysis of the trial. ALX Oncology focuses on developing therapies to enhance the immune system's ability to combat cancer. More details about the presentation will be available on the company's website following the event.
Potential Positives
- Updated results from the Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at a prestigious medical conference, highlighting the company's advancements in cancer treatment.
- The trial's focus on evorpacept, an investigational CD47-blocking therapeutic, showcases ALX Oncology's commitment to innovative cancer therapies that could improve patient outcomes.
- The presentation of significant trial results by a respected medical professional enhances the company's credibility and visibility within the oncology community.
- Highlighting a multi-center international trial indicates broad interest and collaboration in ALX Oncology's research efforts, which may attract further investment and partnership opportunities.
Potential Negatives
- Acceptance of updated results for oral presentation may imply previous concerns or setbacks in the trial's outcomes, potentially impacting investor confidence.
- The necessity for further clinical trials indicated by the ongoing evaluation of evorpacept suggests that the product is still far from market readiness.
- The focus on a specific cancer type (HER2-positive gastric/gastroesophageal junction cancer) may limit the commercial potential of evorpacept if the results are not broadly applicable to other indications.
FAQ
What is ALX Oncology presenting at ASCO 2025?
ALX Oncology will present updated results from its Phase 2 ASPEN-06 clinical trial at the ASCO Gastrointestinal Cancers Symposium.
When is the ASCO Gastrointestinal Cancers Symposium taking place?
The symposium will be held in San Francisco from January 23 to 25, 2025.
What is the focus of the ASPEN-06 clinical trial?
The trial evaluates evorpacept combined with other treatments for patients with HER2-positive gastric/gastroesophageal junction cancer.
Who will present the findings of the ASPEN-06 study?
Dr. Kohei Shitara will present the findings during the oral presentation.
Where can I find copies of the presentation?
Copies of the presentations will be available in the Publications section of ALX Oncology's website after the meeting.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALXO Insider Trading Activity
$ALXO insiders have traded $ALXO stock on the open market 9 times in the past 6 months. Of those trades, 1 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $ALXO stock by insiders over the last 6 months:
- REKHA HEMRAJANI purchased 30,000 shares.
- SHELLY PINTO (SVP, FINANCE AND CAO) has traded it 3 times. They made 0 purchases and 3 sales, selling 3,760 shares.
- SOPHIA RANDOLPH (CHIEF MEDICAL OFFICER) has traded it 2 times. They made 0 purchases and 2 sales, selling 4,638 shares.
- JAUME PONS (PRESIDENT & CSO) has traded it 3 times. They made 0 purchases and 3 sales, selling 32,695 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALXO Hedge Fund Activity
We have seen 56 institutional investors add shares of $ALXO stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC added 4,204,735 shares (+inf%) to their portfolio in Q3 2024
- VESTAL POINT CAPITAL, LP removed 3,600,000 shares (-100.0%) from their portfolio in Q3 2024
- CORMORANT ASSET MANAGEMENT, LP removed 3,142,079 shares (-100.0%) from their portfolio in Q2 2024
- FMR LLC removed 1,949,890 shares (-25.0%) from their portfolio in Q3 2024
- ORBIMED ADVISORS LLC removed 1,894,462 shares (-100.0%) from their portfolio in Q3 2024
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,575,605 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 677,178 shares (+51.1%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025.
ASPEN-06 is a randomized, multi-center, international trial ( NCT05002127) evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel (collectively, TRP) against TRP alone for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer, where all patients had received an anti-HER2 agent in prior lines of therapy.
The updated results from the ASPEN-06 study will be detailed in the following oral presentation:
Title:
Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC)
Abstract Number:
332
Presenter:
Kohei Shitara, MD, Director of the Department of Gastrointestinal Oncology, at National Cancer Center Hospital East, Kashiwa in Japan
Presentation Date and Time:
Thursday, January 23, 2025, from 9:15 a.m. – 10:00 a.m. PST
Session Information:
Rapid Oral Abstract Session A: Cancers of the Esophagus and Stomach
Location:
Level 2 Ballroom
Copies of the presentations will be available on the Publications section of ALX Oncology’s website following presentation at the meeting.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at
www.alxoncology.com
and on LinkedIn @
ALX Oncology
.
